Relapse risk assessment of transplantation for patients with chronic myeloid leukaemia

被引:0
|
作者
Fang, Y [1 ]
Gratwohl, A
Van Houwelingen, HC
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Fac Epidemiol & Med Stat, Wuhan 430030, Peoples R China
[2] Kantonsspital, Dept Internal Med, Div Haematol, CH-4031 Basel, Switzerland
[3] Leiden Univ, Med Ctr, Dept Med Stat, Leiden, Netherlands
关键词
relapse; transplantation; bone marrow; chronic myeloid leukaemia;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To analyse the risk factors of relapse before bone marrow transplantation (BMT) and to present the prognostic information as good as possible. Methods A total of 3142 patients, who underwent the allogeneic blood or bone marrow transplantation between 1989 and 1997 and were documented in the European Group for Blood and Marrow transplantation (EBMT), were included. Six possible risk factors including type of donor, stage of disease, age, gender, donor-recipient sex combination and the waiting time from diagnosis to transplation of relapse were considered. The time to relapse was analysed by Kaplan-Meier curves and Cox regression with stratification on prognostic factors that did not satisfy the Proportional Hazard Assumption. Results An amount of 447 patients relapsed out of all 3142 patients. The relapse rate was 14.2%. Type of donor and stage of disease showed a clear prognostic effect, but failed the proportional hazard assumption. Therefore, the data were stratified on the combination of type of donor and stage of disease. Within these strata an additional significant effect of age could be observed. Relative risk of age, 40 vs age < 40 was 1.32 (95% confidence interval 1.09 - 1.59). The prognostic model is summarized graphically. Conclusions The combination of type of donor, stage of disease and age of recipient at transplantation are important prognostic factors for relapse after BMT.
引用
收藏
页码:305 / 308
页数:4
相关论文
共 50 条
  • [21] Imatinib mesylate for treatment of relapse after allogeneic haematopoietic stem cell transplantation for chronic myeloid leukaemia
    Arqueros, V
    Espigares, A
    Roman, J
    Martin, A
    Jimenez, A
    Fernandez, C
    Capote, M
    Molina, J
    Heiniger, A
    Torres, A
    BONE MARROW TRANSPLANTATION, 2006, 37 : S228 - S228
  • [22] Imatinib mesylate for the treatment of relapse of chronic myeloid leukaemia after allogeneic stem cell transplantation.
    Olavarria, E
    Fischer, T
    Ottmann, O
    Clark, R
    Bandini, G
    Byrne, J
    Lipton, J
    Niederwieser, D
    Goldman, J
    BLOOD, 2002, 100 (11) : 329B - 329B
  • [23] Prediction of relapse risk by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukaemia
    Rubio, MT
    Asnafi, V
    Delabesse, E
    Damaj, G
    Dhedin, N
    Varet, BR
    Buzyn, A
    Macintyre, EA
    BLOOD, 2005, 106 (11) : 571A - 572A
  • [24] Bone marrow transplantation for chronic myeloid leukaemia: The effects of differing criteria for defining chronic phase on probabilities of survival and relapse
    Savage, DG
    Szydlo, RM
    Chase, A
    Apperley, JF
    Goldman, JM
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (01) : 30 - 35
  • [25] Autologous bone marrow transplantation reduces relapse in acute myeloid leukaemia
    Mayor, S
    BRITISH MEDICAL JOURNAL, 1998, 316 (7134): : 799 - 799
  • [26] Outcome of haematopoietic stem cell transplantation in patients with atypical chronic myeloid leukaemia
    Koldehoff, M
    Beelen, DW
    Trenschel, R
    Steckel, NK
    Peceny, R
    Ditschkowski, M
    Hlinka, M
    Elmaagacli, AH
    BONE MARROW TRANSPLANTATION, 2005, 35 : S234 - S234
  • [27] Immunoprofile of patients with chronic myeloid leukaemia
    Petrackova, Martina
    Humlova, Zuzana
    Klamova, Hana
    Duskova, Martina
    Lucansky, Vincent
    Janatkova, Ivana
    Hindos, Miroslav
    Vonka, Vladimir
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 32 : S48 - S48
  • [28] BCL-XL - a biomarker to predict chronic myeloid leukaemia patients at risk of molecular relapse when TKI treatment is discontinued
    Lucas, C.
    Austin, G.
    Holcroft, A.
    Knight, K.
    Varadarjan, S.
    Clark, R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 55 - 55
  • [29] When is chronic myeloid leukaemia 'cured'? Relapse post allogeneic bone marrow transplantation after 32 years
    Bolaji, M.
    Knight, K.
    Patel, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 202 - 202
  • [30] Prognosis of patients with a second relapse of acute myeloid leukaemia.
    Stoiser, B
    Knoebel, P
    Fonatsch, C
    Haas, OA
    Mitterbauer, G
    Geissler, K
    Valent, P
    Sperr, W
    Pabinger, I
    Lechner, K
    Jaeger, U
    BLOOD, 2000, 96 (11) : 105A - 105A